CHI no		Service/Hospitals/Dept. etc. Ward/Team:	NHS
First name	DOB	vvara/Tearn.	Lanarkshire
	Sex: M F	Appendix 1 - Individual Unlicensed 8	2 Hiak
Address			
		Risk Off Label Medicine Application	Form
or attach addr	ressograph label here	Date: Time:	(24 hou
entifies as			(= : : : : :
This form is to be	used in conjunction w	vith the NHS Lanarkshire Policy for Unlicensed Medicines.	
Before completion	n, you must have read	this policy which identifies your responsibilities.	
Requester details	s		
Prescriber name:		Hospital site:	
		Ward/Out-	
Speciality:		patient dept:	
Contact details:		Date requested:	-
correct dotails.		Date required:	
		Dute required.	
Patient details			
Anticipated usage	(please tick) Sin	gle patient/one-off	
Jnlicensed Medi	cine Details		
Product name: International Nor	n Proprietary Name)		
Proprietary Name			
-	rmaceutical Form:		
Manufacturer (if k	nown):		
Indication:			
Dose/frequency/r			
Duration of Treatr	nent:		
Category of requ	iest:		
		s outside of the marketing authorisation for a licensed medicine	
	-	ered 'high risk' in Appendix 4	
2. The medicine	is an unlicensed medi	icine as described in the above policy	
		complete the following	
-	_	onsidered? (Tick as appropriate):	
	•	ailable to treat or diagnose medical condition.	
The UK licensed product used to treat or diagnose the medical condition is temporarily unavailableThe UK licensed product used to treat or diagnose the medical condition is unsuitable			
	'	censed product available or suitable (provide details):	
5. Patient Safety	• •	product available of ballable (provide actails).	
6. Other (provide			Ш
4	•		
04			
新			
₹\$\$ —			

ratient name.								
Clinical Evidence								
Is there any evidence to support its use for the proposed indication?	Yes	□No						
Is there evidence to support its proposed administration schedule? (dose, duration, concentration for parenteral products and route)	☐ Yes	□No						
Is the active drug currently in a licensed product for use via the same rout of administration e.g. tablet, suspension?	e \[Yes	□No						
Is the product licensed for the specified indication in another country?	Yes	□No	☐ Not known					
UK product licence applied for? If yes, record date of application for licence:	Yes	□No	☐ Not known					
Are other Boards using this medicine? If so, name:	Yes	□No	☐ Not known					
Summarise below the supporting evidence, list references and attach copies of references where available.								
What are the risks to the patient of not using this drug?								
What side effects and significant interactions have been reported? Is any r	monitoring req	uired? Do	escribe:					
Give details of contraindications and any other risks to the patient. Include	e precautions i	n use.						
Will there be any primary care implications? (e.g. need for a shared care p	orotocol) If so, o	describe:						

Patient name:		CHI number:			
Prescriber Consultant Specialist Registrar	· (SpR) GP or	other prescr	riber (Fick one)	
Print name:		Speciality/Directorate:			
Signature:		Date:			
If SpR, state name of patient's consulta	nt:				
Authorisation of Application (pharma	cy – acute senior	pharmacist or lo	ocality	prescribing adviser)	
Name	Designation		Signature & Date		
Medicines Cost (Medicines costing les processes in primary care or go straigh					асу
For medicines costing more than £5,00 but less than £25,000 per patient/year? Approved by acute site Chief of Medic	P ☐ Yes ☐ No	Director (Primary (Care)	Signature	
For medicines costing more than £25,0	00		Signature		
per patient/year? Yes No Approved by acute site Chief of Medic	ine AND Medical	Director,			
or Associate Director (Primary Care)			Signature		
Final process approval					
Approval for use Yes No	Date:				
If no, give reasons					
State restrictions on prescribing/use					
Any further information including proje	cted annual cost p	per patient			
Completed by: (PRINT NAME)	D	Designation of approver:			
Signature:		eate.		Time	